REQUIRED PRICE DISCLOSURES

COLORADO

Information for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131.

LEQEMBI™ (lecanemab-irmb)
FYCOMPA® (perampanel), CIII
HALAVEN® (eribulin mesylate)
LENVIMA® (lenvatinib)
DAYVIGO™ (lemborexant), CIV

VERMONT – SHORT FORMS

Information for Vermont Prescribers of Prescription Drugs Provided Pursuant to Vermont Law 33 V.S.A § 2005a.

FYCOMPA® (perampanel), CIII
LENVIMA® (lenvatinib)
DAYVIGO™ (lemborexant), CIV

WHO WE ARE

hhc Mission
Our Locations
Corporate Responsibility
Leadership
Our History
Collaboration

OUR SCIENCE

Global Pipeline
Disease Areas
Clinical Trials
Discovery
Centers

OUR MEDICINES

Our Products
Manufacturing
Eisai Medical Information
Pharmacy Trade Relations

OUR PATIENT FOCUS

Community Involvement
Magnolia Patient Support
Eisai USA Foundation
Eisai Grants Programs

CAREERS AT EISAI

Find Your Opportunity
Talent Areas
Life at Eisai
Career Growth & Development
Rewards & Benefits
Diversity & Inclusion

MEDIA CENTER CONTACT US VIEW CLINICAL TRIALS

Site Map US Privacy Policy EU/UK Privacy Policy Legal Notices & Industry Practices Eisai Co. Ltd.

Eisai CA

Eisai EU

This is the website of Eisai Inc., a US company. This site is intended for US residents only. The health information contained
herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All
decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

YOU’RE ABOUT TO LEAVE US.EISAI.COM

By clicking on the CONTINUE button you will be leaving the Eisai Inc. U.S. website. Eisai assumes no responsibility for, and exercises no control over, the accuracy or information on this external website.